
Please try another search
Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025. Hyperion DeFi, Inc. was founded in 2014 and is based in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Robert N. Weinreb | - | - | Member of Scientific Advisory Board |
Pamela F. Gallin | - | - | Member of Scientific Advisory Board |
Mark Bullimore | - | 2019 | Member of Scientific Advisory Board |
Jason Jones | - | 2022 | Member of Scientific Advisory Board |
Rachel Jacobson | 51 | 2022 | Independent Director |
Ellen R. Strahlman | 68 | 2022 | Independent Director |
Michael S. Geltzeiler | 66 | 2023 | Independent Director |
James C. Tsai | - | - | Member of Scientific Advisory Board |
April Jasper | - | 2019 | Member of Scientific Advisory Board |
Nathan M. Radcliffe | - | 2023 | Member of Scientific Advisory Board |
Francis Mah | - | 2022 | Scientific Advisory Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review